Plus therapeutics presents positive clinical trial results at the 2024 sno/asco cns metastases conference

Plus' cnside leptomeningeal metastases (lm) forsee trial met key primary and secondary endpoints cnside more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (csf) cytology and influenced clinical management decisions in over 90% of lm cases austin, texas, aug. 13, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, presented data from the foresee study of its cnside platform for the diagnosis and management of lm.
PSTV Ratings Summary
PSTV Quant Ranking